# Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma

> **NCT06723457** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Northwestern University** · enrollment: 34 (estimated)

## Conditions studied

- Recurrent B-Cell Non-Hodgkin Lymphoma
- Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder
- Refractory B-Cell Non-Hodgkin Lymphoma

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **BIOLOGICAL:** Epcoritamab
- **DRUG:** Lenalidomide
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT06723457
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-07-25
- **Primary completion:** 2027-02-18
- **Final completion:** 2029-02-18
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2026-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06723457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06723457, "Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06723457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*